Popular Articles

Nature Reviews: Drug Discovery Article Describes Design Of Glycomimetic Compounds And Newly "Druggable" Disease Targets
GlycoMimetics, Inc. announced the publication of an article in Nature Reviews: Drug Discovery describing how novel small molecule compounds that mimic carbohydrates can be successfully designed and optimized to treat cancer, inflammatory disorders and other diseases.

PARI Pharma's Nebulized DSCG Shows Results Similar To Inhaled Steroids In Asthma Studies Presented At ATS
This week, Swiss researchers presented positive data from an ongoing Phase II clinical study at the American Thoracic Society (ATS) International Conference that compared PARI Pharma"s inhaled IsoCrom, an isotonic 1% disodium cromoglycate (DSCG) solution, to inhaled corticosteroids (ICS) in 28 children with atopic asthma. Results showed decreases in mean asthma symptom scores without a change in lung function for both groups. These results were achieved with IsoCrom administered via a customized small droplet Investigational eFlow Nebulizer System designed to deliver drugs to the deep lungs. One of the benefits of DSCG is the long track record as an extremely safe drug.
News of the day
Leicester Geneticists Unearth The Roots Of Human Genetic Variation
A new study at the University of Leicester is using advanced single molecule methods to explore processes that lie at the very core of DNA variation in humans.
Oncology

Zimbabwean PM To Meet With Clinton, Obama In Appeal For Foreign Aid

Zimbabwean Prime Minister Morgan Tsvangirai met with U.S. lawmakers in Washington, D.C., Wednesday in an attempt to secure donations for a country in economic collapse, ZimOnline reports. Tsvangirai"s visit is part of "a three-week trip to America and Europe to try to drum up financial support for the power-sharing government," entered into with his political rival, President Robert Mugabe in February, according to ZimOnline (ZimOnline, 6/11). Tsvangirai will meet with Secretary of State Hillary Rodham Clinton on Thursday before meeting President Barack Obama on Friday, VOA News reports (Zulu/Chiripasi, VOA News, 6/10). SAPA/News24 writes, "Obama and Tsvangirai will "discuss the difficult road ahead in Zimbabwe, including how the United States can support the forces of reform as they work to bring the rule of law, respect for human rights, and free and fair elections back to Zimbabwe," the White House said" (SAPA/News24.com, 6/9). "It will be important for the U.S. to give transitional support to us, because the alternative" - such as an increase in hyperinflation, poverty and violence - "is too ghastly if we fail," Tsvangirai said (Magee, Dow Jones Newswires/Wall Street Journal, 6/10). Zimbabwe"s economic crisis has led to a breakdown of basic social services in the country, complicated by a cholera crisis that has infected about 100,000 people and killed more than 4,200. In early June, the U.N. increased its appeal for foreign aid from $550 million to $718 million to meet Zimbabwe"s growing humanitarian crisis (Kaiser Daily Global Health Policy Report, 6/2). However, U.S. leaders are hesitant, Reuters reports. "The top U.S. diplomat for Africa, Johnnie Carson, said this week that Washington was troubled by the absence of reform in Zimbabwe and had no plans for now to offer major aid or lift sanctions against Mugabe. Western aid is only beginning to trickle in - and all of it is bypassing the government," writes Reuters (Reuters, 6/10). NPR"s All Things Considered examines the task ahead of Tsvangirai in convincing U.S. leaders to "to lift sanctions and put some trust in his power-sharing arrangement" (Kelemen, NPR, 6/10). This information was reprinted from globalhealth.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives and sign up for email delivery at globalhealth.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):